Migraine and headache:

Indications for NURTEC ODT:

Acute treatment of migraine with or without aura.

Limitations of Use:

Not for preventive treatment of migraine.


75mg once (max daily dose). The safety of treating more than 15 migraines in a 30-day period has not been established.


Not established.


Discontinue if hypersensitivity reaction occurs; treat appropriately. Severe hepatic impairment (Child-Pugh C) or ESRD (CrCl <15mL/min): avoid. Dialysis: not studied. Pregnancy. Nursing mothers.

Pharmacologic Class:

Calcitonin gene-related peptide (CGRP) receptor antagonist.


Potentiated by strong CYP3A4 inhibitors (eg, itraconazole); avoid concomitant use. May be potentiated by moderate CYP3A4, P-gp, or BCRP inhibitors. Avoid another dose of Nurtec ODT within 48hrs when used with moderate CYP3A4 inhibitors. May be antagonized by moderate or strong CYP3A inducers (eg, rifampin); avoid concomitant use.

Adverse Reactions:

Nausea; delayed serious hypersensitivity.


CYP3A4 (primarily), CYP2C9 (minor).


Fecal, renal. Half-life: ~11 hours.

Generic Availability:


How Supplied:

ODT tabs—8